Correction - Canaccord Genuity maintains a 'Hold' on ISIS Pharmaceuticals (ISIS)
Tweet
Share
E-mailGet Alerts ISIS Hot Sheet
Price: $57.56 --0%
Rating Summary:
7 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
7 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Correction - Canaccord Genuity maintains a 'Hold' on ISIS Pharmaceuticals (NASDAQ: ISIS) price target of $9.00.
Analyst, Salveen Richter, said, "ISIS reported a Q1 top- and bottom-line beat and provided a detailed update on the pipeline. The focus remains on Kynamro ahead of a CHMP opinion on E.U. approval (HoFH and severe HeFH) expected in mid-’12. In addition, given a 10-month standard review (Jan 29, 2013 PDUFA), we expect a likely FDA panel in late-Q3/early Q4 (shared with AEGR’s lomitapide). Management stated that a pre-approval inspection of the manufacturing facility for E.U. approval went well. We continue to be encouraged by ISIS' vast and diverse pipeline – APOCIII (high triglycerides) entered P2, TTR (TTR amyloidosis, partnered with GSK) is slated to enter a P2/3 in H2/12, FXI (clotting in total knee replacement) and SMN (spinal muscular atrophy, partnered with BIIB) are expected to advance into P2 studies in H2/12 and YE12, respectively – as well as by the company's ability to attract lucrative partnerships. However, we recognize that the pipeline is highly leveraged to the regulatory success of Kynamro."
Analyst, Salveen Richter, said, "ISIS reported a Q1 top- and bottom-line beat and provided a detailed update on the pipeline. The focus remains on Kynamro ahead of a CHMP opinion on E.U. approval (HoFH and severe HeFH) expected in mid-’12. In addition, given a 10-month standard review (Jan 29, 2013 PDUFA), we expect a likely FDA panel in late-Q3/early Q4 (shared with AEGR’s lomitapide). Management stated that a pre-approval inspection of the manufacturing facility for E.U. approval went well. We continue to be encouraged by ISIS' vast and diverse pipeline – APOCIII (high triglycerides) entered P2, TTR (TTR amyloidosis, partnered with GSK) is slated to enter a P2/3 in H2/12, FXI (clotting in total knee replacement) and SMN (spinal muscular atrophy, partnered with BIIB) are expected to advance into P2 studies in H2/12 and YE12, respectively – as well as by the company's ability to attract lucrative partnerships. However, we recognize that the pipeline is highly leveraged to the regulatory success of Kynamro."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
- Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
